Pregabalin
Diabetic Polyneuropathy
Syeda Khatoon e Jannat Welfare FoundationSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Diabetic Polyneuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine University of Rochester | Phase 4 | BB |
(±)-TRAMADOL Turku University Hospital | Phase 4 | BB |
Capsaicin Thammasat University | Phase 2/3 | B |
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | B |
Adezunap Apurano Pharmaceuticals GmbH | Phase 3 | B |
View all 20 →
Same molecule, other indications
Pregabalin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →